Annual EBITDA
-$518.20 M
-$479.80 M-1249.48%
31 December 2023
Summary:
Emergent BioSolutions annual earnings before interest, taxes, depreciation & amortization is currently -$518.20 million, with the most recent change of -$479.80 million (-1249.48%) on 31 December 2023. During the last 3 years, it has fallen by -$1.08 billion (-192.92%). EBS annual EBITDA is now -192.92% below its all-time high of $557.70 million, reached on 31 December 2020.EBS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$177.10 M
+$394.80 M+181.35%
30 September 2024
Summary:
Emergent BioSolutions quarterly earnings before interest, taxes, depreciation & amortization is currently $177.10 million, with the most recent change of +$394.80 million (+181.35%) on 30 September 2024. Over the past year, it has increased by +$395.30 million (+181.16%). EBS quarterly EBITDA is now -39.99% below its all-time high of $295.10 million, reached on 31 December 2020.EBS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$20.50 M
+$395.30 M+105.47%
30 September 2024
Summary:
Emergent BioSolutions TTM earnings before interest, taxes, depreciation & amortization is currently $20.50 million, with the most recent change of +$395.30 million (+105.47%) on 30 September 2024. Over the past year, it has increased by +$548.40 million (+103.88%). EBS TTM EBITDA is now -96.92% below its all-time high of $664.60 million, reached on 31 March 2021.EBS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1249.5% | +181.2% | +103.9% |
| 3 y3 years | -192.9% | +4125.0% | -95.6% |
| 5 y5 years | -437.4% | +82.8% | -86.8% |
EBS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -192.9% | at low | -39.9% | +181.2% | -95.6% | +103.9% |
| 5 y | 5 years | -192.9% | at low | -40.0% | +181.2% | -96.9% | +103.9% |
| alltime | all time | -192.9% | at low | -40.0% | +181.2% | -96.9% | +103.9% |
Emergent BioSolutions EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $177.10 M(-181.4%) | $20.50 M(-105.5%) |
| June 2024 | - | -$217.70 M(-438.6%) | -$374.80 M(+8.4%) |
| Mar 2024 | - | $64.30 M(-2109.4%) | -$345.80 M(-33.3%) |
| Dec 2023 | -$518.20 M(+1249.5%) | -$3.20 M(-98.5%) | -$518.20 M(-1.8%) |
| Sept 2023 | - | -$218.20 M(+15.6%) | -$527.90 M(+57.0%) |
| June 2023 | - | -$188.70 M(+74.6%) | -$336.20 M(+88.9%) |
| Mar 2023 | - | -$108.10 M(+738.0%) | -$178.00 M(+414.5%) |
| Dec 2022 | -$38.40 M(-108.3%) | -$12.90 M(-51.3%) | -$34.60 M(-112.7%) |
| Sept 2022 | - | -$26.50 M(-13.1%) | $272.80 M(-7.5%) |
| June 2022 | - | -$30.50 M(-186.4%) | $294.90 M(-21.2%) |
| Mar 2022 | - | $35.30 M(-88.0%) | $374.40 M(-18.9%) |
| Dec 2021 | $461.50 M(-17.2%) | $294.50 M(-6793.2%) | $461.50 M(-0.1%) |
| Sept 2021 | - | -$4.40 M(-109.0%) | $462.10 M(-17.2%) |
| June 2021 | - | $49.00 M(-60.0%) | $557.90 M(-16.1%) |
| Mar 2021 | - | $122.40 M(-58.5%) | $664.60 M(+19.2%) |
| Dec 2020 | $557.70 M(+146.2%) | $295.10 M(+222.9%) | $557.70 M(+50.3%) |
| Sept 2020 | - | $91.40 M(-41.3%) | $371.10 M(-1.5%) |
| June 2020 | - | $155.70 M(+904.5%) | $376.60 M(+54.5%) |
| Mar 2020 | - | $15.50 M(-85.7%) | $243.80 M(+7.5%) |
| Dec 2019 | $226.50 M(+47.5%) | $108.50 M(+12.0%) | $226.70 M(+46.4%) |
| Sept 2019 | - | $96.90 M(+323.1%) | $154.90 M(+67.5%) |
| June 2019 | - | $22.90 M(-1531.3%) | $92.50 M(-37.8%) |
| Mar 2019 | - | -$1.60 M(-104.4%) | $148.80 M(-3.1%) |
| Dec 2018 | $153.60 M(-8.5%) | $36.70 M(+6.4%) | $153.50 M(-15.8%) |
| Sept 2018 | - | $34.50 M(-56.4%) | $182.29 M(-11.5%) |
| June 2018 | - | $79.20 M(+2454.8%) | $205.89 M(+41.8%) |
| Mar 2018 | - | $3.10 M(-95.3%) | $145.15 M(-13.5%) |
| Dec 2017 | $167.80 M(+15.7%) | $65.49 M(+12.7%) | $167.80 M(+2.3%) |
| Sept 2017 | - | $58.11 M(+214.8%) | $163.98 M(+8.0%) |
| June 2017 | - | $18.46 M(-28.3%) | $151.86 M(+8.1%) |
| Mar 2017 | - | $25.75 M(-58.2%) | $140.53 M(-3.1%) |
| Dec 2016 | $145.00 M(-18.3%) | $61.66 M(+34.1%) | $145.00 M(-8.0%) |
| Sept 2016 | - | $45.99 M(+544.9%) | $157.56 M(-14.3%) |
| June 2016 | - | $7.13 M(-76.4%) | $183.91 M(-11.1%) |
| Mar 2016 | - | $30.22 M(-59.3%) | $206.77 M(+31.7%) |
| Dec 2015 | $177.57 M(+42.2%) | $74.22 M(+2.6%) | $156.96 M(-6.3%) |
| Sept 2015 | - | $72.34 M(+141.2%) | $167.52 M(+23.5%) |
| June 2015 | - | $29.99 M(-253.1%) | $135.68 M(+10.0%) |
| Mar 2015 | - | -$19.60 M(-123.1%) | $123.36 M(-1.2%) |
| Dec 2014 | $124.89 M(+102.2%) | $84.78 M(+109.3%) | $124.89 M(+82.1%) |
| Sept 2014 | - | $40.50 M(+129.2%) | $68.60 M(+33.0%) |
| June 2014 | - | $17.67 M(-197.8%) | $51.56 M(-2.4%) |
| Mar 2014 | - | -$18.07 M(-163.4%) | $52.84 M(-14.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | $61.76 M(+42.7%) | $28.49 M(+21.4%) | $61.76 M(+1.1%) |
| Sept 2013 | - | $23.47 M(+23.8%) | $61.08 M(+21.6%) |
| June 2013 | - | $18.95 M(-307.2%) | $50.24 M(+15.7%) |
| Mar 2013 | - | -$9.15 M(-132.9%) | $43.41 M(+0.3%) |
| Dec 2012 | $43.27 M(+4.8%) | $27.81 M(+120.3%) | $43.27 M(-32.0%) |
| Sept 2012 | - | $12.63 M(+4.1%) | $63.66 M(+15.9%) |
| June 2012 | - | $12.13 M(-230.6%) | $54.91 M(-15.9%) |
| Mar 2012 | - | -$9.29 M(-119.3%) | $65.25 M(+58.0%) |
| Dec 2011 | $41.30 M(-48.0%) | $48.19 M(+1142.4%) | $41.30 M(+37.4%) |
| Sept 2011 | - | $3.88 M(-82.7%) | $30.07 M(-36.3%) |
| June 2011 | - | $22.47 M(-167.6%) | $47.20 M(+14.4%) |
| Mar 2011 | - | -$33.24 M(-189.9%) | $41.27 M(-48.0%) |
| Dec 2010 | $79.36 M(+70.6%) | $36.95 M(+75.8%) | $79.36 M(+64.6%) |
| Sept 2010 | - | $21.01 M(+27.0%) | $48.22 M(+94.0%) |
| June 2010 | - | $16.54 M(+240.8%) | $24.86 M(-23.7%) |
| Mar 2010 | - | $4.85 M(-16.5%) | $32.57 M(-30.0%) |
| Dec 2009 | $46.52 M(+25.6%) | $5.81 M(-347.4%) | $46.52 M(+3.1%) |
| Sept 2009 | - | -$2.35 M(-109.7%) | $45.11 M(-29.6%) |
| June 2009 | - | $24.25 M(+29.0%) | $64.08 M(+44.9%) |
| Mar 2009 | - | $18.80 M(+327.0%) | $44.23 M(+15.4%) |
| Dec 2008 | $37.02 M(-2.3%) | $4.40 M(-73.5%) | $38.33 M(-51.1%) |
| Sept 2008 | - | $16.62 M(+278.3%) | $78.30 M(+16.2%) |
| June 2008 | - | $4.39 M(-66.0%) | $67.37 M(+21.5%) |
| Mar 2008 | - | $12.91 M(-70.9%) | $55.45 M(+46.3%) |
| Dec 2007 | $37.91 M(-12.3%) | $44.38 M(+680.3%) | $37.91 M(-2.5%) |
| Sept 2007 | - | $5.69 M(-175.6%) | $38.88 M(-10.4%) |
| June 2007 | - | -$7.52 M(+62.4%) | $43.39 M(-40.4%) |
| Mar 2007 | - | -$4.63 M(-110.2%) | $72.86 M(-26.7%) |
| Dec 2006 | $43.22 M(-16.0%) | $45.35 M(+344.7%) | $99.44 M(+558.3%) |
| Sept 2006 | - | $10.20 M(-53.5%) | $15.11 M(-55.4%) |
| June 2006 | - | $21.95 M(0.0%) | $33.87 M(-17.2%) |
| Mar 2006 | - | $21.95 M(-156.3%) | $40.89 M(-14.6%) |
| Dec 2005 | $51.46 M(+247.3%) | -$38.99 M(-234.6%) | $47.91 M(+28.7%) |
| Sept 2005 | - | $28.97 M(0.0%) | $37.23 M(+27.8%) |
| June 2005 | - | $28.97 M(0.0%) | $29.14 M(+38.5%) |
| Mar 2005 | - | $28.97 M(-158.3%) | $21.05 M(+62.5%) |
| Dec 2004 | $14.82 M(-73.4%) | -$49.67 M(-337.9%) | $12.95 M(-79.3%) |
| Sept 2004 | - | $20.87 M(0.0%) | $62.62 M(+50.0%) |
| June 2004 | - | $20.87 M(0.0%) | $41.75 M(+100.0%) |
| Mar 2004 | - | $20.87 M | $20.87 M |
| Dec 2003 | $55.77 M(+47.7%) | - | - |
| Dec 2002 | $37.77 M(-16.6%) | - | - |
| Dec 2001 | $45.31 M | - | - |
FAQ
- What is Emergent BioSolutions annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Emergent BioSolutions?
- What is Emergent BioSolutions annual EBITDA year-on-year change?
- What is Emergent BioSolutions quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly EBITDA year-on-year change?
- What is Emergent BioSolutions TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Emergent BioSolutions?
- What is Emergent BioSolutions TTM EBITDA year-on-year change?
What is Emergent BioSolutions annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of EBS is -$518.20 M
What is the all time high annual EBITDA for Emergent BioSolutions?
Emergent BioSolutions all-time high annual earnings before interest, taxes, depreciation & amortization is $557.70 M
What is Emergent BioSolutions annual EBITDA year-on-year change?
Over the past year, EBS annual earnings before interest, taxes, depreciation & amortization has changed by -$479.80 M (-1249.48%)
What is Emergent BioSolutions quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of EBS is $177.10 M
What is the all time high quarterly EBITDA for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly earnings before interest, taxes, depreciation & amortization is $295.10 M
What is Emergent BioSolutions quarterly EBITDA year-on-year change?
Over the past year, EBS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$395.30 M (+181.16%)
What is Emergent BioSolutions TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of EBS is $20.50 M
What is the all time high TTM EBITDA for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM earnings before interest, taxes, depreciation & amortization is $664.60 M
What is Emergent BioSolutions TTM EBITDA year-on-year change?
Over the past year, EBS TTM earnings before interest, taxes, depreciation & amortization has changed by +$548.40 M (+103.88%)